Analysts Are Bullish on These Healthcare Stocks: SPNC, HZNP

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectranetics (NASDAQ: SPNC), Horizon Pharma Inc (NASDAQ: HZNP) and Verona Pharma Plc (NASDAQ: VRNA) with bullish sentiments.

Spectranetics (NASDAQ: SPNC)

In a report released today, Suraj Kalia from Northland Securities reiterated a Buy rating on Spectranetics (NASDAQ: SPNC), with a price target of $32. The company’s shares opened today at $38.40, close to its 52-week high of $38.50.

According to TipRanks.com, Kalia is a 4-star analyst with an average return of 6.7% and a 54.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Xtant Medical Holdings, and Edwards Lifesciences.

Currently, the analyst consensus on Spectranetics is Strong Buy and the average price target is $33.70, representing a -12.2% downside.

In a report released today, Needham also reiterated a Buy rating on the stock with a $38.50 price target.
Horizon Pharma Inc (NASDAQ: HZNP)

In a report released yesterday, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Horizon Pharma Inc (NASDAQ: HZNP), with a price target of $20. The company’s shares opened today at $11.58, close to its 52-week high of $23.44.

According to TipRanks.com, Samimy is a 5-star analyst with an average return of 12.6% and a 52.9% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Corcept Therapeutics Inc, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Horizon Pharma Inc is Strong Buy and the average price target is $15.71, representing a 35.7% upside.

In a report issued on June 15, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $13 price target.
Verona Pharma Plc (NASDAQ: VRNA)

Stifel Nicolaus analyst Thomas Shrader reiterated a Buy rating on Verona Pharma Plc (NASDAQ: VRNA) yesterday and set a price target of $22. The company’s shares opened today at $11.86, close to its 52-week high of $17.50.

According to TipRanks.com, Shrader is a 5-star analyst with an average return of 25.7% and a 55.9% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Threshold Pharmaceuticals, and Inovio Pharmaceuticals.

Verona Pharma Plc has an analyst consensus of Strong Buy, with a price target consensus of $24.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.